PMID- 11689197
OWN - NLM
STAT- MEDLINE
DCOM- 20011207
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 428
IP  - 3
DP  - 2001 Oct 12
TI  - Effect of trapidil on effector functions of monocytes related to atherosclerotic 
      plaque.
PG  - 371-9
AB  - The infiltration and activation of inflammatory cells play an important role in 
      the formation and stability of coronary atherosclerotic plaque in patients with 
      acute coronary syndrome. In this study, we evaluated the effect of trapidil, an 
      anti-platelet agent, on atheroma-related functions of human T cells and 
      monocytes. Trapidil and anti-CD154 (CD40 ligand) antibody inhibited the increase 
      of procoagulant activity in the mixed lymphocyte reaction; trapidil also 
      suppressed the induction of tissue factor, monocyte chemoattractant protein-1 
      (MCP-1) and matrix metalloproteinase-9 in the mixed lymphocyte reaction. Trapidil 
      did not alter CD154 expression on isolated T cells, but it diminished CD40 
      expression on isolated monocytes and human monocytic leukemia THP-1 cells 
      stimulated with interferon-gamma. Moreover, trapidil reduced MCP-1 production of 
      isolated monocytes and THP-1 cells stimulated with interferon-gamma plus 
      CD154-transfected cells. This effect was not seen with other tested anti-platelet 
      agents and coronary vasodilators. In conclusion, trapidil directly acts on 
      monocytes/macrophages to lower their susceptibility to CD154 on T cells.
FAU - Kato, Y
AU  - Kato Y
AD  - Research Center, Mochida Pharmaceutical Co., Ltd., 722 Jimba-aza-Uenohara, 
      Gotemba, 412-8524, Shizuoka, Japan. yutakato@mochida.co.jp
FAU - Tsuda, T
AU  - Tsuda T
FAU - Hosaka, Y
AU  - Hosaka Y
FAU - Takahashi, T
AU  - Takahashi T
FAU - Shirakawa, K
AU  - Shirakawa K
FAU - Furusako, S
AU  - Furusako S
FAU - Mizuguchi, K
AU  - Mizuguchi K
FAU - Mochizuki, H
AU  - Mochizuki H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (CD40 Antigens)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 147205-72-9 (CD40 Ligand)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 9035-58-9 (Thromboplastin)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
RN  - EYG5Y6355E (Trapidil)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/pharmacology
MH  - Arteriosclerosis/pathology/*prevention & control
MH  - CD40 Antigens/biosynthesis
MH  - CD40 Ligand/biosynthesis/immunology
MH  - Cell Line
MH  - Chemokine CCL2/metabolism
MH  - Coculture Techniques
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Interferon-gamma/pharmacology
MH  - Lymphocyte Culture Test, Mixed
MH  - Matrix Metalloproteinase 9/drug effects/metabolism
MH  - Monocytes/*drug effects/metabolism/pathology
MH  - Platelet Aggregation Inhibitors/*pharmacology
MH  - T-Lymphocytes/drug effects/metabolism
MH  - Thromboplastin/biosynthesis/drug effects
MH  - Trapidil/*pharmacology
MH  - Tumor Cells, Cultured/drug effects/metabolism
EDAT- 2001/11/02 10:00
MHDA- 2002/01/05 10:01
CRDT- 2001/11/02 10:00
PHST- 2001/11/02 10:00 [pubmed]
PHST- 2002/01/05 10:01 [medline]
PHST- 2001/11/02 10:00 [entrez]
AID - S001429990101336X [pii]
AID - 10.1016/s0014-2999(01)01336-x [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2001 Oct 12;428(3):371-9. doi: 10.1016/s0014-2999(01)01336-x.